Drug Profile
Research programme: cancer therapeutics - Galapagos NV
Alternative Names: '1790 - Galapagos NV; GLPG 1790; Triple-negative breast cancer therapy - Galapagos NVLatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Galapagos NV
- Class Small molecules
- Mechanism of Action EphA2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma; Triple negative breast cancer
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Malignant-melanoma in Belgium
- 16 Jul 2016 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in Belgium (PO)
- 18 Mar 2014 Pharmacodynamics and adverse events data from a preclinical trial in triple-negative Breast cancer released by Galapagos NV